Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7
|
作者：
Kollmannsberger, Christian [1 ]
Mitchell, Teresa [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期
关键词：
RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;
D O I：
10.1053/j.seminoncol.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：499 / 510
页数：12
相关论文
共 50 条
  • [21] Pulmonary toxicities from targeted therapies: a review
    Barber, Nicholas A.
    Ganti, Apar Kishor
    TARGETED ONCOLOGY, 2011, 6 (04) : 235 - 243
  • [22] Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
    Seruga, B.
    Gan, H. K.
    Knox, J. J.
    CURRENT ONCOLOGY, 2009, 16 : S54 - S61
  • [23] Renal toxicity of targeted therapies
    Kelly, Ronan J.
    Billemont, Bertrand
    Rixe, Olivier
    TARGETED ONCOLOGY, 2009, 4 (02) : 121 - 133
  • [24] Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
    Shepard, Dale R.
    Garcia, Jorge A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 795 - 805
  • [25] Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
    Lainez, Nuria
    Garcia-Donas, Jesus
    Esteban, Emilio
    Puente, Javier
    Isabel Saez, M.
    Gallardo, Enrique
    Pinto-Marin, Alvaro
    Vazquez-Estevez, Sergio
    Leon, Luis
    Garcia-Carbonero, Icar
    Suarez-Rodriguez, Cristina
    Molins, Carmen
    Climent-Duran, Miguel A.
    Lazaro-Quintela, Martin
    Gonzalez del Alba, Aranzazu
    Jose Mendez-Vidal, Maria
    Chirivella, Isabel
    Afonso, Francisco J.
    Lopez-Brea, Marta
    Sala-Gonzalez, Nuria
    Domenech, Montserrat
    Basterretxea, Laura
    Santander-Lobera, Carmen
    Gil-Arnaiz, Irene
    Fernandez, Ovidio
    Caballero-Diaz, Cristina
    Mellado, Begona
    Marrupe, David
    Garcia-Sanchez, Jose
    Sanchez-Escribano, Ricardo
    Fernandez Parra, Eva
    Villa Guzman, Jose C.
    Martinez-Ortega, Esther
    Belen Gonzalez, Maria
    Moran, Marina
    Suarez-Paniagua, Beatriz
    Lecumberri, Maria J.
    Castellano, Daniel
    BMC CANCER, 2016, 16
  • [26] Targeted therapies for renal cell carcinoma: understanding their impact on survival
    Pal, Sumanta Kumar
    Figlin, Robert A.
    TARGETED ONCOLOGY, 2010, 5 (02) : 131 - 138
  • [27] The world of targeted therapies in kidney cancers: pitfalls, tips and tricks
    Vallard, Alexis
    Trone, Jane-Chloe
    Langrand-Escure, Julien
    Espenel, Sophie
    Guy, Jean-Baptiste
    Rancoule, Chloe
    Xia, Yaoxiong
    Hamrouni, Anis El Meddeb
    Ben Mrad, Majed
    Magne, Nicolas
    ONCOTARGETS AND THERAPY, 2017, 10 : 1375 - 1380
  • [28] The flaws in assessing and reporting the toxicities of oral targeted therapies Everolimus as an example
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2023, 50 (1-2) : 1 - 6
  • [29] Management of side-effects of targeted therapies in renal cancer: cardiovascular side-effects
    Ederhy, Stephane
    Duclos, Brigitte
    Mahammedi, Hakim
    Doublet, Jean-Dominique
    BULLETIN DU CANCER, 2011, 98 : S19 - S34
  • [30] Targeted therapies: sequential and combined treatments
    Gross-Goupil, M.
    Escudier, B.
    BULLETIN DU CANCER, 2010, 97 : S65 - S71
12345